Inventor
NICHOLAS ANTHONY
US15 patents
⚠️ This page may combine multiple inventors who share the name “NICHOLAS ANTHONY”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ARROWHEAD PHARMACEUTICALS INC
13 patentsUS11180529B2Nov 23, 2021
Alpha-v beta-6 integrin ligands and uses thereof
ARROWHEAD PHARMACEUTICALS INC3 citations71
US11629349B2Apr 18, 2023
RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC3 citations70
US11549112B1Jan 10, 2023
RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC3 citations70
US11214802B2Jan 4, 2022
RNAi agents for inhibiting expression of alpha-ENaC and methods of use
ARROWHEAD PHARMACEUTICALS INC0 citations61
US10590416B2Mar 17, 2020
RNAi agents for inhibiting expression of alpha-ENaC and methods of use
ARROWHEAD PHARMACEUTICALS INC1 citations61
US12582718B2Mar 24, 2026
Integrin targeting ligands and uses thereof
ARROWHEAD PHARMACEUTICALS INC0 citations60
US12173086B2Dec 24, 2024
Alpha-v beta-6 integrin ligands and uses thereof
ARROWHEAD PHARMACEUTICALS INC0 citations60
US11912997B2Feb 27, 2024
RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC0 citations59
US12054718B2Aug 6, 2024
RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC0 citations58
US12365897B2Jul 22, 2025
RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC0 citations57
US11845937B2Dec 19, 2023
RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC1 citations55
US12486502B2Dec 2, 2025
RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC0 citations53
US12221610B2Feb 11, 2025
RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC0 citations50